

Title (en)

USE OF CBX CANNABINOID RECEPTOR MODULATORS AS POTASSIUM CHANNEL MODULATORS

Title (de)

VERWENDUNG VON CBX CANNABINOID-REZEPTOR-MODULATOREN UND KALIUMKANAL-MODULATOREN

Title (fr)

UTILISATION DE MODULATEURS DE RÉCEPTEURS AUX CANNABINOÏDES CBX EN TANT QUE MODULATEURS DE CANAUX POTASSIUM

Publication

**EP 2012775 A1 20090114 (EN)**

Application

**EP 07728372 A 20070420**

Priority

- EP 2007053915 W 20070420
- EP 06113190 A 20060427
- EP 07728372 A 20070420

Abstract (en)

[origin: WO2007125049A1] The invention is directed to the use of at least one CB<sub>x</sub> modulator wherein the CB<sub>x</sub> modulator is selected from the group consisting of CB<sub>1</sub> agonists; CB<sub>2</sub> agonists; CB<sub>2</sub> partial agonists; CB<sub>2</sub> antagonists; CB<sub>2</sub> inverse agonists; and dually acting compounds which are both a CB<sub>1</sub> agonist and a CB<sub>2</sub> agonist; and mixtures thereof, as K<sub>ATP</sub> channel modulator for the prophylaxis, treatment, delayed progression, delayed onset and/or inhibition of a variety of disease conditions including obesity, diabetes mellitus, metabolic syndrome, syndrome X, insulinoma, familial hyperinsulemic hypoglycemia, male pattern baldness, detrusor hyperreactivity, asthma, neuroprotection, epilepsy, analgesia, cardioprotection, angina, cardioplegia, arrhythmia, coronary spasm, peripheral vascular disease, cerebral vasospasm, appetite regulation, neurodegeneration, pain - including neuropathic pain and chronic pain - and impotence in mammals and humans. The invention further relates to methods of treating, preventing, delaying progression of, delaying onset of and/or inhibiting a variety of disease conditions including obesity, diabetes mellitus, metabolic syndrome, syndrome X, insulinoma, familial hyperinsulemic hypoglycemia, male pattern baldness, detrusor hyperreactivity, asthma, neuroprotection, epilepsy, analgesia, cardioprotection, angina, cardioplegia, arrhythmia, coronary spasm, peripheral vascular disease, cerebral vasospasm, appetite regulation, neurodegeneration, pain - including neuropathic pain and chronic pain - and impotence in mammals and humans comprising administering to a subject in need thereof an effective amount of at least one CB<sub>x</sub> modulator having K<sub>ATP</sub> channel modulating properties.

IPC 8 full level

**A61K 31/353** (2006.01); **A61K 31/09** (2006.01); **A61K 31/415** (2006.01); **A61K 31/425** (2006.01); **A61K 31/454** (2006.01);  
**A61K 31/5415** (2006.01); **A61K 31/542** (2006.01); **A61P 3/04** (2006.01); **A61P 3/10** (2006.01); **A61P 9/06** (2006.01); **A61P 9/10** (2006.01);  
**A61P 13/10** (2006.01); **A61P 15/10** (2006.01); **A61P 17/14** (2006.01); **A61P 25/28** (2006.01)

CPC (source: EP)

**A61K 31/09** (2013.01); **A61K 31/353** (2013.01); **A61K 31/415** (2013.01); **A61K 31/425** (2013.01); **A61K 31/454** (2013.01);  
**A61K 31/5415** (2013.01); **A61K 31/542** (2013.01); **A61P 3/00** (2017.12); **A61P 3/04** (2017.12); **A61P 3/06** (2017.12); **A61P 3/10** (2017.12);  
**A61P 9/00** (2017.12); **A61P 9/06** (2017.12); **A61P 9/10** (2017.12); **A61P 9/12** (2017.12); **A61P 11/06** (2017.12); **A61P 13/00** (2017.12);  
**A61P 13/10** (2017.12); **A61P 15/00** (2017.12); **A61P 15/10** (2017.12); **A61P 17/00** (2017.12); **A61P 17/14** (2017.12); **A61P 19/06** (2017.12);  
**A61P 25/00** (2017.12); **A61P 25/04** (2017.12); **A61P 25/08** (2017.12); **A61P 25/28** (2017.12); **A61P 35/00** (2017.12); **A61P 43/00** (2017.12)

Citation (search report)

See references of WO 2007125049A1

Designated contracting state (EPC)

AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC MT NL PL PT RO SE SI SK TR

Designated extension state (EPC)

AL BA HR MK RS

DOCDB simple family (publication)

**WO 2007125049 A1 20071108**; AR 060626 A1 20080702; AU 2007245734 A1 20071108; CA 2650567 A1 20071108;  
CN 101431994 A 20090513; EP 2012775 A1 20090114; JP 2009534440 A 20090924; MX 2008013285 A 20081024;  
RU 2008146591 A 20100610; TW 200812576 A 20080316

DOCDB simple family (application)

**EP 2007053915 W 20070420**; AR P070101748 A 20070423; AU 2007245734 A 20070420; CA 2650567 A 20070420;  
CN 200780015186 A 20070420; EP 07728372 A 20070420; JP 2009507043 A 20070420; MX 2008013285 A 20070420;  
RU 2008146591 A 20070420; TW 96114781 A 20070426